Parallax moves one step closer to a finished coronavirus test by securing antigens and anitbodies to use as markers

Parallax Health Sciences Inc (OTCMKTS:PRLX) announced Tuesday that it has selected the antigens and antibodies that it will use as the markers in its rapid coronavirus (COVID-19) diagnostic test. The test is being developed on Parallax’s FDA-cleared and patented Target Diagnostics Test Platform, and the company believes it could be ready for the public by summer.  “I am pleased to have this stage of the test development process behind us and look forward to getting into a lab and testing these COVID-19 markers on our Target cartridge,” President David Stark said in a statement. “We understand that there is an immediate need for COVID-19 screen tests in the face of this historic pandemic, and believe that this proprietary test would be available at the earliest by summer.” READ: Parallax Health accepting US orders for its coronavirus Point-of-Care diagnostics kits Even as other companies are working to bring their own coronavirus tests to the market, CEO Paul Arena is confident in Parallax’s product and glad to see others helping to fight the pandemic. “We understand there are other companies getting COVID-19 tests to market, and we at Parallax welcome all companies who can help with this tragic pandemic,” Arena said. “We believe that our four-stage platform, including testing; data management and disease tracking; remote patient monitoring; and telehealth and behavioral intervention is a strong holistic solution to a pandemic such as the one we face today and will, sadly, face in the near future, according to the experts' forecasts." “We are positioning our proprietary Target Analyzer along multiple paths in our pursuit of testing solutions for COVID-19 and we are currently negotiating with diagnostic firms in and outside of the US,” he added. Parallax, based in Santa Monica, is an outcomes-driven telehealth company that focuses on cost-effective remote diagnosis, treatment and monitoring of patients with chronic diseases. Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com  Follow him on Twitter @andrew_kessel